Potential of bacteriophages and their lysins in the treatment of MRSA: Current status and future perspectives

BioDrugs

Volumn 25, Issue 6, 2011, Pages 347-355

  Borysowski, Jan ^a   Łobocka, Małgorzata ^b,c   Międzybrodzki, Ryszard ^d   Weber Dabrowska, Beata ^d   Górski, Andrzej ^a,d  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^d INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Antibacterials; Bacteriophages; Methicillin resistant Staphylococcus aureus infections; Peptide antibiotics

Indexed keywords

ANTIBIOTIC AGENT; DNA; LYSINE;

ARTICLE; BACTERIAL VIRULENCE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOLYSIS; DISEASE CONTROL; DNA PACKAGING; DRUG DELIVERY SYSTEM; DRUG SAFETY; GENE TARGETING; HAND WASHING; HOSPITAL INFECTION; HOST SUSCEPTIBILITY; LYSOGENIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PATIENT SAFETY; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROPHYLAXIS; SEPTICEMIA; STAPHYLOCOCCUS PHAGE;

EID: 80555127438     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11595610-000000000-00000     Document Type: Article

References (98)

1. Campbell A. The future of bacteriophage biology. NatRev Genet 2003; 4: 471-7
2. Sulakvelidze A, Alavidze Z, Morris Jr JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649-59
3. Sulakvelidze A, Kutter E. Phage therapy in humans. In: Kutter E, Sulakvelidze A, editors. Bacteriophages: biology and applications. Boca Raton (FL): CRC Press, 2005: 381-436
4. Sulakvelidze A. Phage therapy: an attractive option for dealing with antibioticresistant bacterial infections. Drug Discov Today 2005; 10: 807-9
5. Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009; 18: 237-43
6. Wright A, Hawkins CH, Anggard EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibioticresistant Pseudomonas aeruginosa: a preliminary report of efficacy. Clin Otolaryngol 2009; 34: 349-57
7. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 2008; 11: 393-400
8. Borysowski J, Weber-Dabrowska B, Górski A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med 2006; 231: 366-77
9. Jevons MP. Celbenin-resistant staphylococci. Br Med J 1961; 1: 124-5
10. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7: 629-41
11. Bancroft EA. Antimicrobial resistance: its not just for hospitals. JAMA 2007; 298: 1803-4
12. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in theUnited States. JAMA2007; 298: 1763-71
13. Gupta MR, Valentine VG, Walker Jr JE, et al. Clinical spectrum of grampositive infections in lung transplantation. Transpl Infect Dis 2009; 11: 424-31
14. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113-22
15. Reygaert W. Focus: methicillin-resistant Staphylococcus aureus (MRSA). Clin Lab Sci 2009; 22: 109-10
16. Corriere MD, Decker CF. MRSA: an evolving pathogen. Dis Mon 2008; 54: 751-5
17. van Cleef BA, Monnet DL, Voss A, et al. Livestock-associated methicillinresistant Staphylococcus aureus in humans, Europe. Emerg Infect Dis 2011; 17: 502-5
18. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008; 197: 1226-34
19. Lucet JC, Paoletti X, Demontpion C, et al. Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household members. Arch Int Med 2009; 169: 1372-8
20. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century: a clinical super-challenge. New Eng J Med 2009; 360: 439-43
21. Sakoulas G, Moellering Jr RC. Increasing antibiotic resistance among methicillin resistant Staphylococcus aureus strains. Clin Inf Dis 2008; 46 (Suppl. 5): S360-7
22. Merril C, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Disc 2003; 2: 489-97
23. Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol 2009; 17: 66-72
24. Górski A, Miedzybrodzki R, Borysowski J, et al. Bacteriophage therapy for the treatment of infections. Curr Opin Invest Drugs 2009; 10: 766-74
25. Bruttin A, Brü ssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. AntimicrobAgents Chemother 2005; 49: 2874-8
26. FDA. Food additives permitted for direct addition to food for human consumption: bacteriophage preparation. FDA Federal Register 2006; 71: 47729-32
27. AckermannHW. 5500 Phages examined in the electron microscope. Arch Virol 2007; 152: 227-43
28. Ackermann HW, Kropinski AM. Curated list of prokaryote viruses with fully sequenced genomes. Res Microbiol 2007; 158: 555-66
29. Daniel A, Bonnen PE, Fischetti VA. First complete genome sequence of two Staphylococcus epidermidis bacteriophages. J Bacteriol 2007; 189: 2086-100
30. Ma XX, Ito T, Kondo Y, et al. Two different Panton-Valentine leukocidin phage lineages predominate in Japan. J Clin Microbiol 2008; 46: 3246-58
31. Kwan T, Liu J, DuBow M, et al. The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci U S A 2005; 102: 5174-9
32. Vandersteegen K, Mattheus W, Ceyssens PJ, et al. Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. PLoS One 2011; 6: e24418
33. Pantůcek R, Rosypalová A, Doskar J, et al. The polyvalent staphylococcal phage phi812: its host-range mutants and related phages. Virology 1998; 246: 241-52
34. Klumpp J, Lavigne R, Loessner MJ, et al. The SPO1-related bacteriophages. Arch Virol 2010; 155: 1547-61
35. + C content. J Bacteriol 2004; 186: 2862-71
36. Ulatowska MI. Structural and functional analysis of polyvalent staphylococcal bacteriophage A5W [PhD thesis]. Warsaw: Institute of Biochemistry and Biophysics of the Polish Academy of Sciences, 2010
37. Kvachadze L, Balarjishvili N, Meskhi T, et al. Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 2011 Sep; 4 (5): 643-50
38. Stewart CR, Casjens SR, Cresawn SG, et al. The genome of Bacillus subtilis bacteriophage SPO1. J Mol Biol 2009; 388: 48-70
39. Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009; 4 (3): e4944
40. Hsieh SE, Lo HH, Chen ST, et al. Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2. Appl Environ Microbiol 2011; 77: 756-61
41. O'Flaherty S, Ross RP, Meaney W, et al. Potential of the polyvalent antistaphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Appl Environ Microbiol 2005; 71: 1836-42
42. Gill JJ, Pacan JC, Carson ME, et al. Efficacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrob Agents Chemother 2006; 50: 2912-8
43. Synnott AJ, Kuang Y, Kurimoto M, et al. Isolation from sewage influent and characterization of novel Staphylococcus aureus bacteriophages with wide host ranges and potent lytic capabilities. Appl Environ Microbiol 2009; 75: 4483-90
44. Dabrowska K, Skaradziński G, Kurzepa A, et al. The effects of staphylococcal bacteriophage lysates on cancer cells in vitro. Clin Exp Med 2010; 10: 81-5
45. Zimecki M, Artym J, Kocieba M, et al. Prophylactic effect of bacteriophages on mice subjected to chemotherapy-induced immunosuppression and bone marrow transplant upon infection with Staphylococcus aureus. Med Microbiol Immunol 2010; 199: 71-9
46. Vybiral D, Taká c M, Loessner M, et al. Complete nucleotide sequence and molecular characterization of two lytic Staphylococcus aureus phages: 44AHJD and P68. FEMS Microbiol Lett 2003; 219: 275-83
47. Meijer WJ, Horcajadas JA, Salas M. Phi29 family of phages. Microbiol Mol Biol Rev 2001; 65: 261-87
48. Lavigne R, Seto D, Mahadevan P, et al. Unifying classical and molecular taxonomic classification: analysis of the Podoviridae using BLASTP-based tools. Res Microbiol 2008; 159: 406-14
49. Son JS, Lee SJ, Jun SY, et al. Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Appl Microbiol Biotechnol 2010; 86: 1439-49
50. Anderson ES, Williams RE. Bacteriophage typing of enteric pathogens and staphylococci and its use in epidemiology. J Clin Pathol 1956; 9: 94-127
51. Cerca N, Oliveira R, Azeredo J. Susceptibility of Staphylococcus epidermidis planktonic cells and biofilms to the lytic action of staphylococcus bacteriophage K. Lett Appl Microbiol 2007; 45: 313-7
52. Sau K, Gupta SK, Sau S, et al. Synonymous codon usage bias in 16 Staphylococcus aureus phages: implication in phage therapy. Virus Res 2005; 113: 123-31
53. Anderson D, Bodley JW. Role of RNA in bacteriophage phi 29 DNA packaging. J Struct Biol 1990; 104: 70-4
54. Bjornsti MA, Reilly BE, Anderson DL. Morphogenesis of bacteriophage phi29 of Bacillus subtilis: DNA-gp3 intermediate in in vivo and in vitro assembly. J Virol 1982; 41: 508-17
55. Klumpp J, Dorscht J, Lurz R, et al. The terminally redundant, nonpermuted genome of Listeria bacteriophage A511: a model for the SPO1-like myoviruses of gram-positive bacteria. J Bacteriol 2008; 190: 5753-65
56. Valpuesta JM, Donate LE, Mier C, et al. RNA-mediated specificity of DNA packaging into hybrid lambda/phi29 proheads. EMBO J 1993; 12: 4453-9
57. + 1 translational frameshifting in structural protein synthesis. Mol Microbiol 2003; 50: 303-17
58. Rees PJ, Fry BA. The morphology of staphylococcal bacteriophageKandDNA metabolism in infected Staphylococcus aureus. J Gen Virol 1981; 53: 293-307
59. Matsuzaki S, YasudaM, Nishikawa H, et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phiMR11. J Infect Dis 2003; 187: 613-24
60. Merril CR, Biswas B, Carlton R, et al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 1996; 93: 3188-92
61. Guttman B, Raya P, Kutter E. Basic phage biology. In: Kutter EB, Sulakvelidze A, editors. Bacteriophages: biology and application. Boca Raton (FL): CRC Press, 2005: 29-66
62. Goerke C, Pantů cek R, Holtfreter S, et al. Diversity of prophages in dominant Staphylococcus aureus clonal lineages. Microbiology 2009; 191: 3462-8
63. Pantů cek R, Doskar J, Rů zicková V, et al. Identification of bacteriophage types and their carriage in Staphylococcus aureus. Arch Virol 2004; 149: 1689-703
64. Das M, Ganguly T, Chattoraj P, et al. Purification and characterization of repressor of temperate S. aureus phage phi11. J BiochemMol Biol. 2007; 40: 740-8
65. Dempsey RM, Carroll D, Kong H, et al. Sau42I, a BcgI-like restrictionmodification system encoded by the Staphylococcus aureus quadrupleconverting phage Phi42. Microbiology 2005; 151: 1301-11
66. Roberts F, Allison GE, Verma NK. Transcription-termination-mediated immunity and its prevention in bacteriophage SfV of Shigella flexneri. J Gen Virol 2007; 88: 3187-97
67. Boyd EF, Brü ssow H. Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends Microbiol 2002; 10: 521-9
68. Brü ssow H, Canchaya C, Hardt WD. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev 2004; 68: 560-602
69. Hoshiba H, Uchiyama J, Shin-ichiro K, et al. Isolation and characterization of a novel Staphylococcus aureus bacteriophage, ø MR25, and its therapeutic potential. Arch Virol 2010; 155: 545-52
70. Cohen S, Sweeney HM, Basu SK. Mutations in prophage phi11 that impair the transducibility of their Staphylococcus aureus lysogens for methicillin resistance. J Bacteriol 1977; 129: 237-45
71. Yacoby I, Shamis M, BarH, et al. Targeting antibacterial agents by using drugcarrying filamentous bacteriophages. Antimicrob Agents Chemother 2006; 50: 2087-97
72. Westwater C, Kasman LM, Schofield DA, et al. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 2003; 47: 1301-7
73. Fairhead H. SASP gene delivery: a novel antibacterial approach. Drug News Perspect 2009; 22: 197-203
74. Phico Therapeutics. Wellcome Trust award-winning company Phico Therapeutics announces success of safety and tolerability trial [media release]. Available from URL: [Accessed 2011 Sep 2]
75. Embleton ML, Nair SP, Heywood W, et al. Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 3690-6
76. Capparelli R, Parlato M, Borriello G, et al. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 2007; 51: 2765-73
77. Goldshahi L, Seed KD, Dennis JJ, et al. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv 2008; 21: 351-60
78. Weber-Dabrowska B, Mulczyk M, Gorski A. Bacteriophage therapy of bacterial infections: an update of our institutes experience. Arch Immunol Ther Exp 2000; 48: 547-51
79. Leszczyń ski P, Weber-Dabrowska B, Kohutnicka M, et al. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker: case report. FoliaMicrobiol 2006; 51: 236-8
80. Mann NH. The potential of phages to prevent MRSA infections. Res Microbiol 2008; 159: 400-5
81. Comeau AM, Té tart F, Trojet SN, et al. Phage-antibiotic synergy (PAS): betalactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2007; 2: e799
82. Rashel M, Uchiyama J, Takemura I, et al. Tail-associated structural protein gp61 of Staphylococcus aureus phage phiMR11 has bifunctional lytic activity. FEMS Microbiol Lett 2008; 284: 9-16
83. Rashel M, Uchiyama J, Ujihara T, et al. Efficient elimination of multidrugresistant Staphylococcus aureus by cloned lysin derived from bacteriophage phiMR11. J Infect Dis 2007; 15: 1237-47
84. O'Flaherty S, Coffey A, Meaney W, et al. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol 2005; 187: 7161-4
85. Loessner MJ,Gaeng S,Wendlinger G, et al. The two-component lysis system of Staphylococcus aureus bacteriophage Twort: a large TTG-start holing and an associated amidase endolysin. FEMS Microbiol Lett 1998; 162: 265-74
86. Loessner MJ, Gaeng S, Scherer S. Evidence for a holing-like protein gene fully embedded out of frame in the endolysin gene of Staphylococcus aureus bacteriophage 187. J Bacteriol 1999; 181: 4452-60
87. Obeso JM, Martinez B, Rodriguez A, et al. Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against Staphylococcus aureus in milk. Int J Food Microbiol 2008; 128: 212-8
88. Gu J, Xu W, Lei L, et al. LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2011; 49: 111-7
89. Navarre WW, Ton-That H, Faull KF, et al. Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi11: identification of a D-alanyl-glycine endopeptidase activity. J Biol Chem 1999; 274: 15847-56
90. Donovan DM, Lardeo M, Foster-Frey J. Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. FEMS Microbiol Lett 2006; 265: 133-9
91. Takac M, Blasi U. Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 2934-40
92. Manoharadas S, Witte A, Blasi U. Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J Biotechnol 2009; 139: 118-23
93. Daniel A, Euler C, Collin M, et al. Synergism between a novel chimeric lysine and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 1603-12
94. Sass P, Bierbaum G. Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol 2007; 73: 347-52
95. Horgan M, O'Flynn G, Garry J, et al. Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. Appl Environ Microbiol 2009; 75: 872-4
96. Fenton M, Casey PG, Hill C, et al. The truncated phage lysin CHAP(k) eliminates Staphylococcus aureus in the nares of mice. Bioeng Bugs 2010; 1: 404-7
97. Becker SC, Foster-Frey J, Donovan DM. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMSMicrobiol Lett 2008; 287: 185-91
98. Pastagia M, Euler C, Chahales P, et al.Anovel chimeric lysin shows superiority for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother 2011; 55: 738-44